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Abstract 
Background: 
Hepatocellular carcinoma (HCC) ranks second amongst all causes of cancer deaths globally. It is on a rise 
in Pakistan and might represent the most common cancer in adult males. Among women, HCC is the 7th most 
common cancer and 6th most common cancer related death. In Pakistan prevalence of HCC varies from 3.7%-16% 
of malignant tumors and most common cause of HCC is viral hepatitis B, C and D related cirrhosis. Pakistan 
contributes significantly to global burden of hepatitis C, which is a known risk factor for HCC, and has one of the 
highest prevalence rates (>3%) in the world. 
Objective: 
To find out the difference of small hemangioma from small hepatic cellular carcinoma by using tri- phasic helical 
Computed Tomography method. 
Methodology: 
In this descriptive study, among 81 patients of suspected hepatocellular carcinoma and hepatocellular hemangioma 
were selected with age and gender discrimination by convenient sampling, at Department of Radiology, UOL 
Teaching hospital Lahore Pakistan. 128 slice Computed Tomography Toshiba Aquilion machine was used.  
Results: 
Out of 81 patients collected with the suspicion of hepatic hemangioma and hepatocellular carcinoma , 41 were 
females and 40 were males who visited radiology department. It shows 50.6% were females and males were 49.4%. 
Out of 81 patients, 25 patients came with HHS and 31 were with HCC. 25.9% develop carcinoma on left side, 
32.1% on right side, 6.2% on R/L side and remaining 35.8% were Nill. Out of 81 patients 8 develop carcinoma on 
anterior, 5 on both, 3 on caudate, 5 on lateral,13 on both 4 on middle, 7 on posterior, 6 on segment eight, 1 on 
segment 4, 1 on segment 7, 1 on segment 2 and remaining 36 sites were nill. 27.5% males develop HCC and 48.8% 
females develop HCC. Out of 81 patients 36.6% female patients develop HHS and 25.0% male patients develop 
HHS.  
Conclusion: 
In this study we conclude that females develop a large number of HCC and HHS than males. Hepatocellular 
carcinoma shows enhancement in early arterial and early washout phase while post-contrast images showing 
capsule-appearance which is relatively specific for HCC. On the other hand, HHS shows uniform enhancement in 
arterial phase and iso- or hyper-attenuating to liver parenchyma on delayed phase. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and is responsible for more 
than 500 000 deaths every year globally (1). In the United States, it most often occurs in patients with preexisting 
cirrhosis or chronic hepatitis.1 In the vast majority of cases, HCC develops on an underlying cirrhosis, although a 
fewcases have been reported in people without this condition. Despite recent improvement, the prognosis of HCC 
remains very poor as only about 10% of the patients can receive curative treatment as orthotopic liver 
transplantation (OLT) or surgical resection, which are unfeasible in most cases due to severe clinical deterioration 
at diagnosis and/or the inaccuracy of preoperative clinical evaluation and staging procedures.2HCC is estimated to 
cause between 250,000 and 1 million deaths annually, worldwide. The usefulness, frequency, and cost-
effectiveness of screening for HCC may well differ in different geographic areas or among different ethnic 
populations, because there may be differences in the incidence and growth characteristics of HCC. There are also 
likely major differences in the epidemiology of hepatitis B between endemic and non endemic areas, particularly 
with respect to age at which the disease is acquired.3 Hepatic hemangioma (HH) is the most common benign 
hepatic tumor. The features may lead to a misdiagnosis of hepatocellular carcinoma (HCC). HCC usually occurs 
as a complication of chronic liver disease and most often arises in cirrhotic livers. The accurate differentiation of 
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HH from HCC with or without cirrhosis is important for patient care and treatment decisions.4High-flow hepatic 
hemangiomas are more likely to accompany arterioportal shunt than slow-flow hemangiomas [1]. It has been 
reported that histopathologic differences exist between the high-flow and the slowflow hemangiomas.5 
Benign tumors of the liver include hemangiomas, focal nodular hyperplasia, and liver cell adenoma. Hepatic 
hemangiomas are the most common benign tumors of the liver, with an incidence in autopsy series ranging from 
0.4% to 7.3%.1 These lesions are considered congenital vascular malformations and enlarge by ectasia rather than 
neoplastic growth. Macroscopically, they are well-circumscribed, reddish-purple, hypervascular lesions that are 
compressible. Histologic analysis of these tumors reveals large blood-filled spaces lined by endothelial cells and 
separated by thin fibrous septa.6 Primary carcinoma of the liver holds a unique position among all human 
neoplasms: first, because of striking differences in racial and geographical distribution, the problem, has world-
wide significance. Second, it is so regularly associated with a chronic degenerative and regenerative disease 
(cirrhosis) of a large parenchymatous organ. Such association is rarely seen in other large organs such as the 
pancreas and kidney. Third, tumors occur spontaneously and can also be easily produced in experimental animals 
by different carcinogenic agents that damage the liver. Lastly, certain inherent difficulties are encountered in both 
the clinical and pathological aspects of the disease. The clinical problem is often one of diagnosing carcinoma in 
the presence of cirrhosis or distinguishing Primary from secondary carcinoma of the liver. From the standpoint of 
pathology, there is such variation in histological structure that the determination of histogenesis and hence 
classification of some neoplasms of the liver have been almost impossible.7 Dual-energy CT performed during 
two consecutive scans or with a dual x-ray source, dual-detector assembly has existed for a number of years and 
yields additional information that is used for material separation at imaging, with potential use in clinical 
applications ( 5–8 ). However, the clinical use of dual-energy CT has been hampered because of motion 
misregistration, high image noise, and excessive radiation exposure caused by long acquisition times ( 8 ). A CT 
scanning mode based on the rapid switching between high- and low-energy data sets from view to view was 
recently introduced. This scanning mode enables precise registration of data sets for creation of accurate material-
decomposition images (eg, water- and iodine-based material-decomposition images) and monochromatic spectral 
images at energy levels ranging from 40 to 140 keV throughout the full 50-cm fi eld of view. The garnet crystal 
detector used, with an extremely fast primary speed (100 times faster than existing detectors) and low afterglow 
(four times lower), and the associated detection system enable simultaneous dual-energy acquisition.4 
While the computed tomographic (CT) and magnetic resonance (MR) imaging characteristics of HCC have 
been documented extensively, HCC can have a variety of appearances. Many radiologists and referring physicians 
would probably regard any hypervascular, noncystic, focal hepatic lesion in a cirrhotic liver as being highly 
suggestive of HCC. In a series of 508 consecutive hepatectomy specimens obtained during liver transplantation, 
Dodd et al (2) found only nine cavernous hemangiomas at gross pathologic examination, and only three of these 
were visualized at preoperative nonhelical CT. This incidence of hemangiomas (1.7% at pathologic examination, 
0.6% at CT) is lower than the frequency with which hemangiomas are encountered at unselected autopsy series 
(3), or at CT in noncirrhotic patients.8 Multiphasic helical computed tomographic (CT) examination of the liver 
following intravenous contrast material injection has become an important technique for the detection and 
characterization of hepatic masses. Several reports (1– 6) have focused on detection of liver tumors with the use 
of multiphasic helical CT, and it has been reported (3) that two-phase (arterial and portal venous phase) helical CT 
is useful in the detection of hypervascular liver tumors. However, only a few reports (7,8) have focused on 
characterization of liver tumors with use of multiphasic helical CT. Most cavernous hemangiomas are easily 
distinguished from malignant hepatic tumors due to characteristic features, such as near isoattenuation with blood 
on nonenhanced images and globular or nodular peripheral enhancement similar to attenuation of blood vessels, 
at rapid CT with bolus administration of contrast material. Because hemangiomas are encountered frequently, 
distinction from hepatic malignancy is an important and common challenge.9 
An arterioportal (AP) shunt associated with a hepatic tumor has been reported to be an important sign that 
the tumor is malignant (5–7), but AP shunts have been believed to be rare in hemangiomas (5,8 –10). However, 
results of more recent studies have shown that AP shunts are not uncommonly seen in hepatic hemangiomas. 
Several authors have reported that a high percentage of hemangiomas (19%–26%) are accompanied by an AP 
shunt (3,11,12). In contrast, most HCCs accompanied by AP shunts tend to be advanced tumors with portal vein 
thrombosis. To our knowledge, a comparison of the prevalence of AP shunts associated with small hemangiomas 
and that associated with HCCs 3 cm in diameter or smaller has not been performed by using two-phase helical CT 
except in one study (13), the results of which revealed that differential diagnosis between early and homogeneously 
enhancing HCC and hemangioma was possible with twophase CT.10 
 
Methods 
In this descriptive study, among 81 patients of suspected hepatocellular carcinoma and hepatocellular hemangioma 
were selected with age and gender discrimination by convenient sampling, at Department of Radiology, UOL 
Teaching hospital Lahore Pakistan. 128 slice Computed Tomography Toshiba Aquilion machine was used. 
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Patients included in this study had a clinical evidence of liver carcinoma. Pregnant patients were excluded in this 
study. 
 
RESULTS  
Out of 81 patients collected with the suspicion of hepatic hemangioma and hepatocellular carcinoma.41 were 
females and 40 were males who visited radiology department. It shows 50.6% were females and males were 49.4%. 
Out of 81 patients, 25 patients came with HHS and 31 were with HCC. 25.9% develop carcinoma on left side, 
32.1% on right side, 6.2% on R/L side and remaining 35.8% were Nill. Out of 81 patients 8 develop carcinoma on 
anterior, 5 on both, 3 on caudate, 5 on lateral,13 on both 4 on middle, 7 on posterior, 6 on segment eight, 1 on 
segment 4, 1 on segment 7, 1 on segment 2 and remaining 36 sites were nill. 27.5% males develop HCC and 48.8% 
females develop HCC. Out of 81 patients 36.6% female patients develop HHS and 25.0% male patients develop 
HHS.  
Gender 
 Frequency Percent Valid Percent Cumulative Percent 
Valid F 41 50.6 50.6 50.6 
M 40 49.4 49.4 100.0 
Total 81 100.0 100.0  
Table 1: Frequency distribution of gender 
 
 
 
Hepatic Hemangiomas 
 Frequency Percent Valid Percent Cumulative Percent 
Valid NO 56 69.1 69.1 69.1 
YES 25 30.9 30.9 100.0 
Total 81 100.0 100.0  
Table 2: Frequency distribution of hepatic hemangiomas 
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Hepatocellular Carcinomas 
 Frequency Percent Valid Percent Cumulative Percent 
Valid NO 50 61.7 61.7 61.7 
YES 31 38.3 38.3 100.0 
Total 81 100.0 100.0  
Table 3: Frequency distribution of hepatocellular carcinoma 
 
 
 
Side 
 Frequency Percent Valid Percent Cumulative Percent 
Valid LEFT 21 25.9 25.9 25.9 
NILL 29 35.8 35.8 61.7 
RIGHT 26 32.1 32.1 93.8 
RIGHT ,LEFT 5 6.2 6.2 100.0 
Total 81 100.0 100.0  
Table 4: Frequency distribution of side 
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Site 
 Frequency Percent Valid Percent Cumulative Percent 
Valid ANTERIOR 8 9.9 9.9 9.9 
BOTH LOBE 5 6.2 6.2 16.0 
CAUDATE 3 3.7 3.7 19.8 
LATERAL 5 6.2 6.2 25.9 
LOBE 13 16.0 16.0 42.0 
MIDDLE 4 4.9 4.9 46.9 
NILL 26 32.1 32.1 79.0 
POSTERIOR 7 8.6 8.6 87.7 
SEGMENT EIGHT 6 7.4 7.4 95.1 
SEGMENT FOUR 1 1.2 1.2 96.3 
SEGMENT SEVEN 1 1.2 1.2 97.5 
SEGMENT SIX 1 1.2 1.2 98.8 
SEGMENT TWO 1 1.2 1.2 100.0 
Total 81 100.0 100.0  
Table 5: Frequency distribution of site 
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Gender * HCC Crosstabulation 
 
HCC 
Total NO YES 
Gender F Count 21 20 41 
% within gender 51.2% 48.8% 100.0% 
M Count 29 11 40 
% within gender 72.5% 27.5% 100.0% 
Total Count 50 31 81 
% within gender 61.7% 38.3% 100.0% 
Table 5: Frequency distribution of gender * HCC Crosstabulation 
 
Gender * HHS Crosstabulation 
 
HHS 
Total NO YES 
gender F Count 26 15 41 
% within gender 63.4% 36.6% 100.0% 
M Count 30 10 40 
% within gender 75.0% 25.0% 100.0% 
Total Count 56 25 81 
% within gender 69.1% 30.9% 100.0% 
Table 5: Frequency distribution of gender * HHS Crosstabulation 
 
 
 
Discussion 
Out of 81 patients collected with the suspicion of hepatic hemangioma and hepatocellular carcinoma. 41 were 
females and 40 were males who visited radiology department. It shows 50.6% were females and males were 49.4%. 
Out of 81 patients, 25 patients came with HHS and 31 were with HCC. 25.9% develop carcinoma on left side, 
32.1% on right side, 6.2% on R/L side and remaining 35.8% were Nill. Out of 81 patients 8 develop carcinoma on 
anterior, 5 on both, 3 on caudate, 5 on lateral,13 on both 4 on middle, 7 on posterior, 6 on segment eight, 1 on 
segment 4, 1 on segment 7, 1 on segment 2 and remaining 36 sites were nill. 27.5% males develop HCC and 48.8% 
females develop HCC. Out of 81 patients 36.6% female patients develop HHS and 25.0% male patients develop 
HHS. Hayashida M et.al conducted a study which results in Forty-three (67%) of 64 lesions showed Grade 4 (n 
=24) or Grade 5 (n = 19) enhancement on arterial-phase CT, indicating hypervascular HCCs on CT (Fig. 1). In 
contrast, 51 (80%) of 64 lesions showed Grade 4 (n =20) or Grade 5 (n =31) enhancement on arterial-phase MR 
imaging, indicating hypervascular HCCs on MR imaging. All of the 43 hypervascular HCCs on arterial-phase CT 
were included in the 51 hypervascular HCCs on MR imaging. The grading score of hypervascular HCCs on 
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arterial-phase MR imaging (mean: 4.61) was significantly (P b.01) higher than that of hypervascular HCCs on 
arterial-phase CT (mean: 4.20), showing better detection of hypervascularity (arterial enhancement) of the lesions 
on arterial-phase MR imaging. Thirty-two (74%) of 43 hypervascular HCCs on CT showed Grade 1 (n =13) or 
Grade 2 (n =19) enhancement on late-phase CT. In contrast, 25 (49%) of 51 hypervascular HCCs on MR imaging 
showed Grade 1 (n =11) or Grade 2 (n =14) enhancement on late-phase MR imaging (Fig. 1). Grading scores of 
hypervascular HCC on late-phase CT (mean: 2.00) were significantly (P b.001) lower than those on MR imaging 
(mean: 2.35), indicating less washout effects for hypervascular HCCs on late-phase MR imaging. Twenty-one 
(33%) of 64 lesions showed Grade 1, 2 or 3 enhancement on arterial-phase CT, indicating hypovascular HCCs on 
CT. All of these 21 hypovascular HCCs on CT showed Grade 1 (n = 10) or Grade 2 (n = 11) enhancement on late-
phase CT seen as hypoattenuation. In contrast, 13 (20%) of 64 lesions showed Grade 1, 2 or 3 enhancement on 
arterialphase MR imaging, indicating hypovascular HCCs on MR imaging. Among these 13 hypovascular HCCs 
on MR imaging, 8 (62%) lesions showed Grade 1 (n = 1) or Grade 2 (n = 7) enhancement on late-phase MR 
imaging, seen as hypointensity. The remaining five (38%) hypovascular HCCs on MR imaging showed Grade 3 
enhancement, seen as isointensity. Grading scores of hypovascular HCCs on latephase images were significantly 
(P b.001) lower on CT than on MR imaging (mean score: 1.52 vs. 2.31), indicating better washout effects for 
hypovascular HCCs on late-phase CT. Although five (38%) hypovascular HCCs were not detected (Grade 3) on 
arterial-phase and late-phase MR imagings, all of these HCCs were visible on unenhanced T1-weighted and/or 
T2-weighted MR images.11 L v, P et.al concluded conventional CT methods, globular enhancement was observed 
in 19 (63%) and 18 (60%) of the 30 HH lesions during the AP and PVP, respectively; in zero and one (11%) of 
the nine HCCcirrhosis lesions during the AP and PVP, respectively; and in four (15%) and three (12%) of the 26 
HCC–no cirrhosis lesions during the AP and PVP, respectively. Attenuation similar to that of the aorta during the 
AP and similar to that of the blood pool during the PVP was observed in 14 (47%) of the 30 HH lesions and in 
none of the HCC lesions (with or without cirrhosis). During the AP, diffuse homogeneous enhancement was noted 
in eight (27%) of the 30 HH lesions, seven (78%) of the nine HCCcirrhosis lesions, and 13 (50%) of the 26 HCC–
no cirrhosis lesions. Using these qualitative criteria, we achieved sensitivities and specifi cities of 67% and 56%, 
respectively, for differentiating between HH and HCC with cirrhosis and 67% and 54%, respectively, for 
differentiating between HH and HCC without cirrhosis during the AP. We achieved sensitivities and specifi cities 
of 83% and 78%, respectively, for differentiating between HH and HCC with cirrhosis and 83% and 84%, 
respectively, for differentiating between HH and HCC without cirrhosis during the PVP.4 Another study was 
conducted by Freeny PC et.al which results inthe patterns of dynamic contrast enhancement in the 58 scans were 
categorized as peripheral in 74% (43 hemangiomas); central (focal zone of contrast enhancement within the center 
of the lesion) in 12% (seven hemangiomas); diffuse (complete, homogeneous contrast enhancement of the entire 
lesion) in 2% (one hemangioma); mixed (central and peripheral) in 9% (five hemangiomas); and absent in 3% 
(two hemangiomas). The degree of isodense fill-in was categorized as complete in 72% (42 hemangiomas), partial 
(a remaining zone of diminished attenuation within the lesion) in 21 % (12 hemangiomas), and none (no fill-in or 
decrease in lesion size) 7% (four hemangiomas). Included in the last group were two hemangiomas in the same 
patient that arose in a diffusely fatty liver. The lesions remained hyperdense on delayed scans and therefore were 
categorized as having no fill-in. The time required to reach complete isodense fill-in was determined for each 
hemangioma. There was no direct relationship to size and time required to reach isodense fill-in, although the 
largest lesion (12 cm) required the longest time (90 mm). Only two of the 42 hemangiomas required more than 30 
mm to reach fill-in (45 and 90 mi respectively). During the delayed scan sequences, 13 lesions remained diffusely 
hyperdense for 5-15 mm before becoming isodense. All lesions that were diffusely hyperdense became isodense. 
In five cases, delayed scans were obtained after isodense fill-in had occurred. These scans showed that the lesions 
subsequently returned to their precontrast appear- ance (hypodense relative to the surrounding hepatic 
parenchyma).12 
 
CONCLUSION 
In this study we conclude that females develop a large number of HCC and HHS than males. Hepatocellular 
carcinoma shows enhancement in early arterial and early washout phase while post-contrast images showing 
capsule-appearance which is relatively specific for HCC. On the other hand, HHS shows uniform enhancement in 
arterial phase and iso- or hyper-attenuating to liver parenchyma on delayed phase. 
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